Literature DB >> 27300348

Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes.

Sung Hye Kong1,2, Seo Young Lee1,2, Ye Seul Yang1,2, Tae Min Kim1,2, Soo Heon Kwak3,4.   

Abstract

Entities:  

Year:  2016        PMID： 27300348     DOI： 10.1007/s00592-016-0872-y

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN： 0940-5429            Impact factor:   4.280


× No keyword cloud information.
  10 in total

1.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Immune Checkpoint Inhibitor-related Endocrinopathies.

Authors:  Difei Lu; Ying Gao
Journal:  J Transl Int Med       Date:  2022-04-02

Review 3.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 4.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 5.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 6.  Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.

Authors:  V Lo Preiato; S Salvagni; C Ricci; A Ardizzoni; U Pagotto; C Pelusi
Journal:  Rev Endocr Metab Disord       Date:  2021-01-06       Impact factor: 6.514

7.  Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.

Authors:  Xiaoying Sun; Raheleh Roudi; Ting Dai; Shangya Chen; Bin Fan; Hongjin Li; Yaqiong Zhou; Min Zhou; Bo Zhu; Chengqian Yin; Bin Li; Xin Li
Journal:  BMC Cancer       Date:  2019-06-10       Impact factor: 4.430

8.  Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.

Authors:  Giulia Lanzolla; Alberto Coppelli; Mirco Cosottini; Stefano Del Prato; Claudio Marcocci; Isabella Lupi
Journal:  J Endocr Soc       Date:  2019-01-08

Review 9.  Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.

Authors:  Ashray Gunjur; Oliver Klein; Damien Kee; Jonathan Cebon
Journal:  J Immunother Cancer       Date:  2019-09-05       Impact factor: 13.751

Review 10.  Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.

Authors:  Xiaofei Huang; Mei Yang; Liu Wang; Libo Li; Xiaowei Zhong
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.